Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells

Acta Pharmacologica Sinica

Volumn 31, Issue 7, 2010, Pages 861-866

  Zhang, Jia Hua ^a   Liu, Li Qiong ^b   He, Yan Li ^a   Kong, Wei Jia ^a   Huang, Shi Ang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

Author keywords

apoptosis; cytokine induced killer cells; Fas; K562 cells; leukemia; mitochondrial transmembrane potential; trans Cinnamaldehyde

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CINNAMALDEHYDE; FAS LIGAND; TRANS CINNAMALDEHYDE; UNCLASSIFIED DRUG; ACROLEIN; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CELL LABELING; CELL STRAIN K 562; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG EFFECTS; GENETICS; K562 CELL LINE; LEUKEMIA; METABOLISM; PATHOLOGY; STEREOISOMERISM; TIME;

ACROLEIN; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CYTOKINE-INDUCED KILLER CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; HUMANS; K562 CELLS; LEUKEMIA; MEMBRANE POTENTIAL, MITOCHONDRIAL; STEREOISOMERISM; TIME FACTORS; UP-REGULATION;

EID: 77954474547     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.76     Document Type: Article

References (22)

1. Ringdén O. Immunotherapy by allogeneic stem cell transplantation. Adv Cancer Res 2007; 97: 25-60.
2. Nencioni A, Grünebach F, Patrone F, Ballestrero A, Brossart P. Protea-some: inhibitors antitumor effects and beyond. Leukemia 2007; 21: 30-36
3. Ka H, Park HJ, Jung HJ, Choi JW, Cho KS, Ha J, et al. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett 2003; 196: 143-152
4. Lee CW, Lee SH, Lee JW, Ban JO, Lee SY, Yoo HS, et al. 2-hydroxy cinnamaldehyde inhibits SW620 colon cancer cell growth through AP-1 inactivation. J Pharmacol Sci 2007; 104: 19-28.
5. Koh WS, Yoon SY, Kwon BM, Jeong TC, Nam KS, Han MY. Cinnamal-dehyde inhibits lymphocyte proliferation and modulates T-cell differentiation. Int J immunopharmacol 1998; 20: 643-660
6. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97: 2923-2931
7. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007; 92: 952-959
8. Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003; 5: 259-272
9. Cholujová D, Jakubíková J, Kubes M, Arendacká B, Sapák M, Ihnatko R, et al. Comparative study of four fuorescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology 2008; 213: 629-640
10. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188: 2375-2380
11. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J. Redox control of cell death. Antioxid Redox Signal 2002; 4: 405-414
12. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530
13. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652
14. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 2000; 49: 335-345
15. Li W, Wang S, Chen C, Zhuang G. Induction of tumor cell apoptosis via Fas/DR5. Cell Mol Immunol 2006; 3: 467-471
16. + T-cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo. Cancer Biother Radiopharm 2006; 21: 276-284
17. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 181-187
18. Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic specifcity against leukemia. Leuk Lymphoma 2003; 44: 1457-1462
19. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1146-1151
20. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-2515
21. Torelli GF, Guarini A, Maggio R, Alferi C, Vitale A, Foà R. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission, Haematologica 2005; 90: 785-792
22. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007; 21: 622-626